Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Guillain-Barre syndrome


Other Names for this Disease

  • Acute autoimmune peripheral neuropathy
  • Acute immune-mediated polyneuropathy
  • Acute inflammatory demyelinating polyneuropathy
  • Acute inflammatory demyelinating polyradiculoneuropathy
  • Acute inflammatory neuropathy
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

I have just recovered from Guillian-Barre syndrome. I want to know if it will affect me again?

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

What is the long-term outlook for individuals with Guillain-Barre syndrome?

Recovery from Guillain-Barre syndrome is not always quick. Many patients reach the point of greatest weakness or paralysis days or weeks after symptoms first occur. Symptoms then stablize at this level for either days, weeks and sometimes, months. The entire recovery period can be as short as a few weeks or as long as a few years. About 30% of patients with Guillain-Barre will still have some weakness after three years. Recurrence of Guillain-Barre is rare but about 3 percent of patients experience this. The risk of recurrence appears to be higher in patients that have a longer disease course, begin treatment at a later stage and have other associated medical conditions.[1][2]
Last updated: 10/23/2012

References
Other Names for this Disease
  • Acute autoimmune peripheral neuropathy
  • Acute immune-mediated polyneuropathy
  • Acute inflammatory demyelinating polyneuropathy
  • Acute inflammatory demyelinating polyradiculoneuropathy
  • Acute inflammatory neuropathy
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.